In the past six months alone, the company’s stock price has increased by a massive 41.5%, reaching $13.07 per share. This was ...

The market expects Viatris (VTRS) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook is ...

Viatris is set to report its fourth-quarter earnings soon, with analysts forecasting a slight decline in profits.

Viatris (VTRS) shares recorded modest gains in the premarket on Thursday after the Xanax maker exceeded Street forecasts with its Q3 2025 financials thanks mainly to growth in emerging markets, and ...

Fintel reports that on January 16, 2026, Argus Research upgraded their outlook for Viatris (NasdaqGS:VTRS) from Hold to Buy. Analyst Price Forecast Suggests 1.60% Upside As of January 13, 2026, the ...

Viatris (NASDAQ:VTRS) shares snapped six straight sessions of gains on Monday, as the stock closed 0.6% lower at $10.13. The healthcare gained 7% in the preceding six sessions. Overall, the stock has ...

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible ...

Viatris Inc. (NASDAQ:VTRS) is one of the top cheap stocks under $20 to buy now. On December 18, Viatris Inc. (NASDAQ:VTRS) announced four recent regulatory milestones spread across all stages of the ...